| 26.21 -0.665 (-2.47%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.97 | 1-year : | 38.51 |
| Resists | First : | 28.22 | Second : | 32.97 |
| Pivot price | 26.75  |
|||
| Supports | First : | 24.72 | Second : | 22.55 |
| MAs | MA(5) : | 26.6 |
MA(20) : | 26.25 |
| MA(100) : | 20.37 |
MA(250) : | 16.87 |
|
| MACD | MACD : | 0.8 |
Signal : | 1 |
| %K %D | K(14,3) : | 50.4 |
D(3) : | 57.5 |
| RSI | RSI(14): 55.2 |
|||
| 52-week | High : | 28.22 | Low : | 8.19 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NRIX ] has closed above bottom band by 22.1%. Bollinger Bands are 48.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 26.92 - 27.06 | 27.06 - 27.16 |
| Low: | 25.76 - 25.94 | 25.94 - 26.09 |
| Close: | 25.96 - 26.23 | 26.23 - 26.45 |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Fri, 28 Aug 2026
BlackRock Inc. Buys New Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Wed, 26 Aug 2026
Elmind Capital LP Makes New Investment in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Wed, 26 Aug 2026
313,236 Shares in Nurix Therapeutics, Inc. $NRIX Acquired by ADAR1 Capital Management LLC - MarketBeat
Wed, 26 Aug 2026
Deutsche Bank AG Takes Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Mon, 24 Aug 2026
Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case (NASDAQ:NRIX) - Seeking Alpha
Thu, 20 Aug 2026
Deep Track Capital, LP Expands Nurix Therapeutics Inc (NRIX) Sta - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 104 (M) |
| Held by Insiders | 7.965e+007 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 17,800 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.5318e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 41.7 % |
| Return on Equity (ttm) | -40.1 % |
| Qtrly Rev. Growth | 3.677e+007 % |
| Gross Profit (p.s.) | -44.42 |
| Sales Per Share | -44.87 |
| EBITDA (p.s.) | -1.69927e+008 |
| Qtrly Earnings Growth | -3.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -294 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.59 |
| Price to Cash Flow | 12.09 |
| Dividend | 0 |
| Forward Dividend | 1.835e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|